Amalia Rubio

Dr. Amalia Rubio

Dpt. Of Medical Biochemistry and Molecular Biology and Immunology, Instituto de Investigaciones Biomédicas de Sevilla, IBIS (University of Seville, HUVR, Junta de Andalucía, CSIC), Seville, Spain
orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2002 in Blood
Verified
Journal Article
Closed access
PDF file
JFJaime M. Franco
Jaime M. Franco
ARAmalia Rubio
Amalia Rubio
MMManuel Martı́nez-Moya
Manuel Martı́nez-Moya
MLManuel Leal
Manuel Leal
EMElena Merchante
Elena Merchante
ELEduardo Lissen
Eduardo Lissen
The origin of T cells after highly active antiretroviral therapy (HAART) in patients infected with human immunodeficiency virus 1 (HIV-1) is now under discussion. The possibility of renewed lymphopoiesis in aged thymuses is still controversial. In this work we combine the analysis of naı̈ve T cells, T-cell receptor excision circles (TRECs), and computed tomography scanning of thymic tissue to further assess whether the thymus is involved in immune reconstitution. Fifteen antiretroviral-naı̈ve HIV-1–infected patients were evaluated during 48 weeks of HAART. At baseline, significant correlation was present among age and both thymic volume and TRECs, and between naı̈ve T cells and TRECs. After starting HAART, there was a significant increase at week 12 in naı̈ve CD4+and CD8+ T cells, TRECs, and thymic volume. The initial net increases in naı̈ve T cells and TREC counts were significantly correlated. Changes in thymic volume and TRECs were also indirectly related; splitting the population into 2 groups of high and low baseline TREC levels, only the group with low TREC levels had significant increases in both TRECs and thymic volume. Thus, the increase in thymic volume might be functional, in response to depleted TREC levels. Taken together, our data strongly suggest a thymic role in immune reconstitution, at least in patients with depleted baseline TREC levels.

26 May 2011 in Journal of Pineal Research
Verified
Journal Article
Closed access
PDF file
Patricia J. LardonePatricia J. Lardone
Patricia J. Lardone
JGJuan M. Guerrero
Juan M. Guerrero
JFJosé M. Fernández-Santos
José M. Fernández-Santos
ARAmalia Rubio
Amalia Rubio
IMInés Martín-Lacave
Inés Martín-Lacave
Antonio Carrillo-VicoAntonio Carrillo-Vico
Antonio Carrillo-Vico

1 December 2012 in Clinica Chimica Acta
Verified
Journal Article
Closed access
HMHada Macher
Hada Macher
JEJUAN JOSE José EGEA-GUERRERO
JUAN JOSE José EGEA-GUERRERO
JRJaume Revuelto-Rey
Jaume Revuelto-Rey
EGElena Gordillo-Escobar
Elena Gordillo-Escobar
JEJudy Enamorado-Enamorado
Judy Enamorado-Enamorado
ARAmalia Rubio
Amalia Rubio

9 December 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
HMHada C. Macher
Hada C. Macher
GSGonzalo Suárez-Artacho
Gonzalo Suárez-Artacho
JGJuan M. Guerrero
Juan M. Guerrero
MBMIGUEL ANGEL GOMEZ BRAVO
MIGUEL ANGEL GOMEZ BRAVO
SÁSara Álvarez-Gómez
Sara Álvarez-Gómez
ARAmalia Rubio
Amalia Rubio
Health assessment of the transplanted organ is very important due to the relationship of long-term survival of organ transplant recipients and health organ maintenance. Nowadays, the measurement of cell-free DNA from grafts in the circulation of transplant recipients has been considered a potential biomarker of organ rejection or transplant associated complications in an attempt to replace or reduce liver biopsy. However, methods developed to date are expensive and extremely time-consuming. Our approach was to measure the SRY gene, as a male organ biomarker, in a setting of sex-mismatched female recipients of male donor organs. Cell-free DNA quantization of the SRY gene was performed by real-time quantitative PCR beforehand, at the moment of transplantation during reperfusion (day 0) and during the stay at the intensive care unit. Beta-globin cell-free DNA levels, a general cellular damage marker, were also quantified. Beta-globin mean values of patients, who accepted the graft without any complications during the first week after surgery, diminished from day 0 until patient stabilization. This decrease was not so evident in patients who suffered some kind of post-transplantation complications. All patients showed an increase in SRY levels at day 0, which decreased during hospitalization. Different complications that did not compromise donated organs showed increased beta-globin levels but no SRY gene levels. However, when a donated organ was damaged the patients exhibited high levels of both genes. Determination of a SRY gene in a female recipient's serum is a clear and specific biomarker of donated organs and may give us important information about graft health in a short period of time by a non-expensive technique. This approach may permit clinicians to maintain a close follow up of the transplanted patient.

1 September 2001 in AIDS
Verified
Journal Article
Closed access
OGOscar Gallego
Oscar Gallego
CMCarmen de Mendoza
Carmen de Mendoza
MEMaría Jesús Pérez Elías
María Jesús Pérez Elías
JGJosep María Guardiola
Josep María Guardiola
JPJosé Pedreira
José Pedreira
VSVincent Soriano
Vincent Soriano
To assess the pattern of drug resistance mutations selected in HIV-1-infected patients failing a first line triple combination therapy including indinavir. Plasma samples from 87 patients collected at the time of the first virological rebound (> 50 HIV-RNA copies/ml) were examined for the presence of drug-resistant genotypes. The mean level of plasma viraemia at rebound was 7824 HIV-1 RNA copies/ml in 73 subjects with good compliance, whereas it was 359 460 HIV-1 RNA copies/ml in 14 patients who admitted to poor adherence. Genetic sequence analysis yielded results for 51 (70%) of the patients having good adherence. More than half of them (26/51, 51%) carried primary mutations associated with resistance to nucleoside analogues. In contrast, primary protease inhibitor resistance mutations were recognized less frequently (14/51, 27%; P < 0.05). Moreover, in 23 (45%) patients there was no evidence of drug-resistant viruses at all. The most frequent drug-resistant genotypes in the reverse transcriptase gene were at codons 184 (n = 19), 215 (n = 14) and 41 (n = 8), whereas for the protease they were at codons 46 (n = 10), 82 (n = 9) and 90 (n = 7). No resistance genotypes were found among non-compliant patients. The overall rate of drug-resistant HIV genotypes was 38% (28/73) in patients with good adherence and who were experiencing a first virological failure under a triple combination regimen including indinavir; resistance to nucleoside analogues was more frequent than resistance to indinavir. Therefore, treatment intensification in those patients without resistance, or a selective substitution of nucleosides in those with resistance limited to these compounds, might be justified.

1 July 2009 in Journal of Pineal Research
Verified
Journal Article
Closed access
PDF file
AGAraceli Gómez‐Corvera
Araceli Gómez‐Corvera
Isabel Cerrillo GarcíaIsabel Cerrillo García
Isabel Cerrillo García
PMPatrocinio Molinero
Patrocinio Molinero
MNMaria Carmen Naranjo
Maria Carmen Naranjo
Patricia J. LardonePatricia J. Lardone
Patricia J. Lardone
ARAmalia Rubio
Amalia Rubio